Histamines and Cortisone in Experimental Anaphylaxis

Total Page:16

File Type:pdf, Size:1020Kb

Histamines and Cortisone in Experimental Anaphylaxis i__ Med.Pharmacol.exp. (Basel) 3.3,189-198 (1965) LSD _ i From the Laboratori Ricerche Farmacelogiche, Farmitalia S.p.A., Milano, Italy _ Synergistic Action of an Anti-5-Hydroxytryptamine, Anti- Histamines and Cortisone in Experimental Anaphylaxis By G. B. FREGNAN and A. H. GLXSSER I The mechanism of anaphylaxis is not yet clearly understood. Symptoms and lesions have been found to be constant for a given animal species but to i differ from one species to another irrespective of the nature of the sensitizing il antigen. The anaphylactic shock can he considered as the result of reactions initiated by the union of antigen and cellular antibody with release of sub- :' stances (histamine, 5-hydroxytryptamine, acetyleholine, bradykinin, slow- reacting substances, heparin, anaphylatoxin, trypsin, etc.), elevation of some electrolyte values (Na, K, CI) in muscle, viscera and bone, and changes of the lipid metabolism of lung tissue. The reactions may vary qualitatively or quanti- i: tatively with the animal species. Among the substances released during anaphylactic shock, 5-hydroxytryptamine (5-HT) and histamine have been supposed to play an important role together in several animals species (such _: as rabbit, rat, and mice) and some attempts to prevent the anaphylactic shock !i with anti-5-HT or anti-histamine drugs have been, at least partially, successful f_ (1, 8, I0, 11, 13, 17, 19, 21, 22, 23). Histamine and slow-reacting substances (SRS-A) are quite important in guinea.pig anaphylaxig, so that anti-histamine and anti-SRS.A drugs had some protective effects (12, 6). However, a stronger protection has been observed when animals have been pretrealed with a drug E or a mixture of drugs having manifold properties so to counteract all the _ cutaneousalterations anaphylaxisseen duringinanamice,phylwhicaxis.h seemsHalpernto beet theal. result(13) shofowedthe simultaneothat passiveus I release of 5-HT and histamine, is almost completely abolished by the simul- _ taneous injection of lysergic acid diethylamide (LSD 25) and mepyramine with a considerable mutual reinforcement of theix: anti-anaphylactic properties. Other evidences of synergism in protecting guinea-pigs from anaphylaxis have been given by Goadb 9 ond SmitA (12) with cortisone and mepyramine and by Collier et al. (6) with acetylsalicylic acid and mepyramine. Owing to. these results, we have studied the anti-anaphylactic effects of associations of drugs, each one counteracting, as specifically as possible, a particular aspect of the anaphylaxis in rats and mice. In consideration of the fact that the anaphylactic shock in rats and in mice is possibly due to 5-HT, histamine, electrolytes and lipids changes we pretreated the animals with anti- 5-HT, anti-histamines and cortisone given either alone or in combination. Received: February 18, 1965. .... _'"..... r'_ r ............. 7 i 190 Ftegnan and GlOsser, Synergistic Action of an Antl-5-HT and anti-histamines block the effect of 5-HT and histamine on some • receptors, while cortisone besides lowering the tissue reserves of 5-HT and histamine (18) would exert an action on the electrolytes and on the lipid meta- ! bolism (0). Among the anti-5.HT, the new drug 1-methyl-8_-carbobenzyloxy. aminomethyl-10a-ergoline maleate (MCE), synthetized in our laboratories (3), has been used because it has a very specific and long-lasting action (2). Materials and Methods Female white mice (15-18 g in weight) and rats (80-100 g in weight) were : used. The mice were sensitized by two i.p. injections (2 ml/mouse) of a mixture ! containing 1 ml of undiluted horse serum and 1 ml of a saline suspension of tIemophilus pertussis vaccine (1,000 millions HP organisms) at two days ! i: interval. The rats received only one i.p. injection (2 ml/rat) of the same _ mixture. The animals were challenged intravenously: mice with 1 ml of un- i: diluted horse serum 26 days after the last sensitizing injection and rats with 0.5 mi of antigen 14-16 days after the sensitizing antigen. These challenging doses consistently produced fatal anaphylactic shock in 84-88Jg of sensitized mice within 10-40 minutes and hypotcnsion in 75.8_g of sensitized rats within 2-5 minutes. The same amounts caused no toxic manifestations in normal unsensitized mice and rats. MCE, given subcutaneously, and cortisone acetate, intramuscularly,were injected 24 hours prior to the challengingdose of antigen. i LSD 25 maleate, mepyramine hydrochloride, chlor-pheniramine maleate, and promethazine hydrochloride were injected subcutaneously 2-3 hours prior to challenge. Acetylsalicylic acid was given intraperitoneally 30-45 minutes prior to challenge. Rats, before the intravenous administration of the antigen, were anesthetized with sodium amobarbital (100 g/kg h.w. intraperitoneally) i and their carotid pressure was recorded on a smoked drum by a mercury manometer. The rectal temperature was measured by a thermocouplc. The probe was inserted into the rectum to a constant depth of 2.5 cm and was . removed after each reading. i Results io Anti-5-HT, anti-histamines, cortisone, and other drugs were studied for their property to protect sensitized rats and mice from anaphylactic shock. For this purpose the hypothermia and the hypotension have been controlled in sensitized rats and the mor- tality in sensitized mice following the intravenous administration of shockdosesof antigen. E[lect of chronic treatment tuith MCE on the sensitization o[ -.:. - ! mice and rats ..... : The animals were treated subcutaneously with 5 mg/kg/day of MCE for 12 days beginning 5 days before the first sensitizing dose :;_ I and ending 5 days after the last sensitizing dose. This treatment did 'C i , > , ii • t t i Anti-5-hydroxytryptamlne, Anti-histamines, and Cortisone... 191 not protect the animals exposed to the challenge demonstrating that MCE did not interfere with the production of antibody by the organism. _, Effect of acute treatment with MCE on the rectal temperature ! o] sensitized rat beIore or alter the shock dose 5-10 mg/kg of MCE given subcutaneously to rats lowered their rectal temperature for 0.8°-1.5°C within the first two hours. The temperature gradually returned to the normal level in about 5-6 _ hours. At the twenty-fourth hour, when the rat temperature was !: quite normal, the ehaUange was given. 90-100_ of the sensitized control animals showed a decrease of their rectal temperature (2°-5°C below the normal temperature within the first two hours} while only 20-30 % of the MCI 0:pretreated animals showed a small decrease (1.5°-2°C}. Effect of acute treatment with MCE, mepyramine and corti- sone on anaphylaxis in rats (blood pressure changes) Table I shows that the MCE (1-10 mg/kg) and mepyramine (25 mg/kg) were scarcely active when given alone, but strongly protected the rats when administered simultaneously: in fact only 28% of the rats gave hypotension. Cortisone (t00 mg/kg) also af- forded a protection of the same degree as that given by MCE associated to mepyramine. TABLE I Reduction of the hypotension following the anaphylaetic shock in sensitized rats by pretreotment with MCE, Mepltramine, and Cortisone % of rats giving • Interval between hypotension N* of Antagonists Dose Route the administration within 2-5 mln ruts mg/kg of antagonists and after i.v. ehall- the challenge enge with 0.5 ml of horse serum* 57 Control - - - 75.8 r 30 MCE 1.0 s.c. 24 h 64.0 _r 28 MCE 10.0 s.c. 24 h 56.0 14 Mepyramine 25.0 s.c. 2-3 h 66.6 12 MCE 1.0 s.c. 24 h 28.0 Mepyramine 25.0 s.c. 2--3 h 11 Cortisone 100.0 i.m. 24 h 36".2 * Rats giving a hypotension ranging from 1 to 10 mm Hg were considered protected. ,_ $_" I :-_',:_z_ o,= _, _z____,_<_:_'_._£'._): ' _=_:,_L_¢_.:,X,.-:_'_,._,-_,j,_ ,, :,,,_:__ i 192 Fregnan and GlOsser, Synergistic Action of an : TABLE II i_ Anti-anaphglactic eHects o/parious drugs in sensitized mice .4 _. % mortality " Interval between within , N ° of Antagonists Dose Route the administration a0-60 rain after mice mg/kg of antagonists and challenge with the challenge I ml of horse serum 115 Control - - - 84.0 27 MCE 1.0 s.c. 24 h 88.8 38 MCE 1.0 s.c. 24 h 73.6 MCE 1.0 s.c. 2-3 h 70 MCE 10.0 s.c. 24 h 71.4 20 LSD 10.0 s.c. 2--3h 70.0 48 Mepyramine 25.0 s.c. 2-3 h 70.8 21 Promethazine 1.0 s.c. 2-3 h 71.4 20 Promethazine 10.0 s.c. 2-3 h 45.0 22 Promethazine 25.0 s.c. 2-3 h 22.7 41 Cortisone 10.0 i.m. 24 h 82.2 20 Cortisone 100.0 i.m. 24 h 0 20 Acetylsalicylic acid 2.5 i.p. 30-45 rain 85.0 22 Acetylsalicylic acid 10.0 i.p. 30--45 rain 82.0 34 Acetylsalicylic acid 100.0 i.p. 30-45 rain 82.3 20 MCE 1.0 s.c. 24 h 75.0 Mepyramine 25.0 s.c. 2-3 h 56 MCE 10.0 s.c. 24 h 50.0 ,, Mepyramine 25.0 s.c. 2-3 h 20 MCE 1.0 s.c. 24 h 55.5 MCE 1.0 s.c. 2--,3 h i Promethazine 1.0 s.c. 2-3 h 23 MCE 10.0 s.c. 24 b 39.2 Prometh_zine 10.0 s.c. 2-3 h 22 MCE 10.0 s.c.
Recommended publications
  • Opioid and Other Substance Use Disorders
    OPIOID AND OTHER SUBSTANCE USE DISODERS Dr Amit Arya Additional Professor Department of Psychiatry KGMU Lucknow What are addictive substances? Any substance which when taken has an ability to change the person’s consciousness, thinking, mood, behaviour and motor functions Leading to take the substance repeatedly (World Health Organisation, 1992) …Also called as psychoactive substances Layman term: “Drugs” Why are certain substances addictive? Intake of any substance – oral, inhalational, injecting Enters the bloodstream Acts on a specific body part, such as heart, lung, stomach, etc. Addictive substances act on brain Addictive Substances act on brain All substances acting on the brain are not addictive Addictive substances I want to primarily act on a particular take that area/group of neurons in the drug again! brain, Leading the individual to repeatedly administer the addictive / psychoactive substance → “drug seeking” behaviour Addictive substances primarily act on a particular area/group of neurons in the brain. Regions controlling emotions, thinking, Frontal region judgement & memory Mid Brain How are addictive substances different from each other? Broad actions Chemical that the drug class of drugs produces on the brain Source of drug Natural/semi- TYPOLOGY synthetic/synthetic Mode of intake Oral/inhalational/ Availability – parenteral legal/illegal? (injections) Typology – Chemical Class Opioids Alcohol Cannabis Volatile solvents Based on chemical class Stimulants Tobacco Sedative- hypnotics Hallucinogens The usual drug-use
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Glucocorticoids with Ketamine and Pentobarbitone- Induced General Anaesthesia in the Rat: Possible Effects on Central Cholinergic Activity
    Br. J. Pharmac. (1984), 82,339-347 Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone- induced general anaesthesia in the rat: possible effects on central cholinergic activity Remy S. Leeuwin, Jan K. van der Wal & Willem Spanjer Pharmacological Laboratory, University of Amsterdam, Polderweg 104,1093 KP Amsterdam, The Netherlands 1 Doses of 100, 150 and 200 igkg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine. The antagonistic effect is increased as the dose is increased. The duration of anaesthesia induced by pentobarbitone is reversed by the cholinesterase inhibitor in doses of 150, 200 and 250 tig kg-1. 2 Choline, in a dose of 50mg kg-, significantly antagonizes the action of the two anaesthetics, whereas hemicholinium-3, an inhibitor of the uptake of choline and the synthesis of acetylcholine, markedly potentiates their action. 3 Dexamethasone induces a significant reduction of the duration of anaesthesia produced by ketamine and pentobarbitone. The potentiation of the anaesthetic effect caused by hemicholinium-3 is also reversed by dexamethasone. 4 The acetylcholine content in rat cerebral cortex is increased after treatment with ketamine and pentobarbitone. 5 Measurements of the course of the plasma level of pentobarbitone do not reveal alterations in the pharmacokinetic profile by either neostigmine or dexamethasone. 6 These results indicate that central cholinergic systems may somehow be involved in the anaesthesia induced by ketamine and pentobarbitone and that the interactions described in this paper may be the result of modification by neostigmine and dexamethasone of the alterations in cholinergic activity caused by the two anaesthetics. Introduction In 1977 Balmer & Wyte showed that physostigmine after completion of the operation was actually pro- antagonized the sedative effects of diazepam and longed.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Involvement of Sigma-1 Receptors in the Antidepressant-Like Effects of Dextromethorphan
    Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan Linda Nguyen, Matthew J. Robson¤, Jason R. Healy, Anna L. Scandinaro, Rae R. Matsumoto* Department of Basic Pharmaceutical Sciences, and Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia, United States of America Abstract Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (s1) receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine whether dextromethorphan elicits antidepressant-like effects and the involvement of s1 receptors in mediating its antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice using the forced swim test. Next, s1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with dextromethorphan to determine the involvement of s receptors in its antidepressant-like effects. Quinidine, a cytochrome P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the s1 receptor. Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with s1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve.
    [Show full text]
  • Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D
    Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders
    ACCEPTED MANUSCRIPT Selectively Bred Rats Page 1 of 75 Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders Richard L. Bell*1, Sheketha R. Hauser1, Tiebing Liang2, Youssef Sari3, Antoinette Maldonado-Devincci4, and Zachary A. Rodd1 1Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA 2Indiana University School of Medicine, Department of Gastroenterology, Indianapolis, IN 46202, USA 3University of Toledo, Department of Pharmacology, Toledo, OH 43614, USA 4North Carolina A&T University, Department of Psychology, Greensboro, NC 27411, USA *Send correspondence to: Richard L. Bell, Ph.D.; Associate Professor; Department of Psychiatry; Indiana University School of Medicine; Neuroscience Research Building, NB300C; 320 West 15th Street; Indianapolis, IN 46202; e-mail: [email protected] MANUSCRIPT Key Words: alcohol use disorder; alcoholism; genetically predisposed; selectively bred; pharmacotherapy; family history positive; AA; HAD; P; msP; sP; UChB; WHP Chemical compounds studied in this article Ethanol (PubChem CID: 702); Acamprosate (PubChem CID: 71158); Baclofen (PubChem CID: 2284); Ceftriaxone (PubChem CID: 5479530); Fluoxetine (PubChem CID: 3386); Naltrexone (PubChem CID: 5360515); Prazosin (PubChem CID: 4893); Rolipram (PubChem CID: 5092); Topiramate (PubChem CID: 5284627); Varenicline (PubChem CID: 5310966) ACCEPTED _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado-Devincci, A., & Rodd, Z. A. (2017). Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.02.004 ACCEPTED MANUSCRIPT Selectively Bred Rats Page 2 of 75 The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence.
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]